Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LW402 Tablets Following Multiple Doses in Healthy Volunteers

NCT07546149 is registered in ClinicalTrials.gov with Shanghai Longwood Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07546149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07546149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LW402 Tablets Following Multiple Doses in Healthy Volunteers
Lead sponsor
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2025
Completion date
December 31, 2025
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety evaluation of escalating doses